Increasingly, new drug development by major pharmaceutical companies relies on in-licensing of innovative therapies. Often there are limited data accompanying these novel entities. By focusing on scientific principles and generating key preclinical and clinical data, discovery companies can improve their valuations. From the lens of a large pharmaceutical company, we highlight key scientific aspects that are assessed to mitigate risk in valuations and deal terms. Our focus is on clinical development aspects for oncology drugs by stage of development. However, these lessons apply equally to other therapeutic areas.

中文翻译：

---

肿瘤药物的科学尽职调查：药理学、转化医学和临床视角。

主要制药公司的新药开发越来越依赖于创新疗法的许可。通常伴随这些新实体的数据有限。通过关注科学原理并生成关键的临床前和临床数据，发现公司可以提高其估值。从一家大型制药公司的角度，我们强调了评估的关键科学方面，以降低估值和交易条款中的风险。我们的重点是按开发阶段划分的肿瘤药物的临床开发方面。然而，这些经验同样适用于其他治疗领域。